Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: M04AA51

Duzallo(allopurinol;lesinurad)

Gout

Marketing Authorisation Holder: Grunenthal GmbH

EMA Authorisation: 23/08/2018

INN: allopurinol;lesinurad

Indication

Duzallo is indicated in adults for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Duzallo — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.